Photo from wikipedia
I read the article titled “Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment… Click to show full abstract
I read the article titled “Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy” by Gibson et al,1 recently published in Circulation , with great interest. The investigators reported that among patients with atrial fibrillation undergoing intracoronary stenting, administration of either rivaroxaban 15 mg daily plus P2Y12 inhibitor monotherapy or 2.5 mg rivaroxaban twice daily plus dual antiplatelet therapy was associated with a …
Journal Title: Circulation
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!